Results 11 to 20 of about 31,417,423 (292)
A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles [PDF]
International Journal of Nanomedicine, 2013 Gerald Bachler, Natalie von Goetz, Konrad Hungerbühler ETH Zurich, Institute for Chemical and Bioengineering, Zurich, Switzerland Abstract: Silver is a strong antibiotic that is increasingly incorporated into consumer products as a bulk, salt, or ...
Bachler G +2 more
doaj +2 more sources
International Journal of Nanomedicine, 2016 Ulrika Carlander,1 Dingsheng Li,2 Olivier Jolliet,2 Claude Emond,3,4 Gunnar Johanson1 1Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 2Department of Environmental Health Sciences, School of Public Health, University of ...
Carlander U +4 more
doaj +1 more source
Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development [PDF]
ADMET and DMPK, 2019 Physiologically based pharmacokinetic (PBPK) modeling is a mechanistic or physiology based mathematical modeling technique which integrates the knowledge from both drug-based properties including physiochemical and biopharmaceutical properties and system
Abdul Naveed Shaik, Ansar Ali Khan
doaj +2 more sources
Physiologically based pharmacokinetic (PBPK) model of chlorzoxazone
, 2023 This repository provides the chlorzoxazone physiologically based pharmacokinetic (PBPK) model. If you have any questions or problems please open an issue FundingMatthias König were supported by the Federal Ministry of Education and Research (BMBF ...
Küttner, Jonas, König, Matthias
core +3 more sources
Physiologically Based Pharmacokinetic Modeling of Nanoparticles [PDF]
Journal of Pharmaceutical Sciences, 2019 Nanoparticles are frequently designed to improve the pharmacokinetics profiles and tissue distribution of small molecules to prolong their systemic circulation, target specific tissue, or widen the therapeutic window. The multifunctionality of nanoparticles is frequently presented as an advantage but also results in distinct and complicated in vivo ...
Dongfen, Yuan +4 more
openaire +2 more sources
Molecules, 2023 Acute kidney injury (AKI) and chronic kidney disease (CKD) have become public health problems due to high morbidity and mortality. Currently, drugs recommended for patients with AKI or CKD are extremely limited, and candidates based on a new mechanism ...
Man Su +8 more
doaj +1 more source
Physiologically Based Pharmacokinetic (PBPK) Models for Ethanol [PDF]
IEEE Transactions on Biomedical Engineering, 2008 Physiologically based pharmacokinetic models have been used to describe the distribution and elimination of ethanol after intravenous administration. These models have been used to estimate the ethanol infusion profile that is sufficient for achieving a prescribed breath ethanol concentration time course in individuals, providing a useful platform for ...
Martin H. Plawecki +4 more
openaire +3 more sources
Frontiers in Pharmacology, 2023 Objective: Chronic kidney disease (CKD) has significant effects on renal clearance of drugs. The application of antibiotics in CKD patients to achieve the desired therapeutic effect is challenging.
Guoliang Deng +11 more
doaj +1 more source
Physiologically based pharmacokinetic (PBPK) model of talinolol
, 2023 <p>This repository provides the talinolol physiologically based pharmacokinetic (PBPK) model.</p> <p>If you have any questions or problems please <a href="https://github.com/matthiaskoenig/talinolol-model/issues">open an issue</
Stemmer Mallol, Beatrice Amelie +1 more
core +2 more sources
A minimal physiologically based pharmacokinetic model for high-dose methotrexate [PDF]
, 2021 Purpose: High-dose methotrexate (HDMTX) is administered for the treatment of a variety of malignant tumors. Wide intra- and inter-individual variabilities characterize the pharmacokinetics of MTX, which is mostly excreted renally.
Pesenti, G., Manca, D., Foppoli, M.
core +2 more sources